Tandem Diabetes Care Stock (NASDAQ:TNDM)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$43.76

52W Range

$13.82 - $53.69

50D Avg

$42.18

200D Avg

$35.29

Market Cap

$2.88B

Avg Vol (3M)

$1.58M

Beta

1.34

Div Yield

-

TNDM Company Profile


Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

2,400

IPO Date

Nov 14, 2013

Website

TNDM Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceJun 24Mar 24Jun 18Mar 18
Supplies and Other$113.88M$105.53M--
Pump$107.88M$87.29M--
Complementary Products--$2.30M$2.10M

Fiscal year ends in Dec 23 | Currency in USD

TNDM Financial Summary


Dec 23Dec 22Dec 21
Revenue$747.72M$801.22M$702.80M
Operating Income$-233.23M$-61.81M$8.81M
Net Income$-222.61M$-94.59M$15.57M
EBITDA$-118.22M$-30.77M$22.65M
Basic EPS$-3.43$-1.47$0.25
Diluted EPS$-3.43$-1.47$0.24

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 02, 24 | 6:36 AM
Q1 24May 02, 24 | 12:00 AM
Q4 23Feb 21, 24 | 10:47 PM

Peer Comparison


TickerCompany
PACBPacific Biosciences of California, Inc.
ABTAbbott Laboratories
PODDInsulet Corporation
SYKStryker Corporation
PENPenumbra, Inc.
MDTMedtronic plc
NNOXNano-X Imaging Ltd.
DXCMDexCom, Inc.
ALGNAlign Technology, Inc.
INSPInspire Medical Systems, Inc.
SWAVShockWave Medical, Inc.